Balyasny Asset Management LLC Protagonist Therapeutics, Inc Transaction History

Balyasny Asset Management LLC

  • $58 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$14.05 - $23.44 $709,567 - $1.18 Million
50,503 New
50,503 $1.16 Million
Q3 2018

Nov 14, 2018
SELL
$6.82 - $11.26 $269,253 - $444,544
-39,480 Closed
0 $0
Q2 2018

Aug 14, 2018
BUY
$5.99 - $9.1 $165,419 - $251,305
27,616 Added 232.77%
39,480 $265,000
Q1 2018

May 15, 2018
BUY
$8.46 - $23.08 $100,369 - $273,821
11,864 New
11,864 $102,000

Others Institutions Holding PTGX

# of Institutions
247
Shares Held
56.4M
Call Options Held
76.3K
Put Options Held
114K
View Full List

About Protagonist Therapeutics, Inc

PTGX Quotes by TradingView
  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.92B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email